Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

DISEASE CHARACTERISTICS:

• Histologically confirmed refractory solid tumor for which no curative standard therapy exists

  • Metastatic disease

• Treated brain metastases that have been stable ≥ 3 months allowed

  • At least 1 week since prior steroids

PATIENT CHARACTERISTICS:

• ECOG performance status of 0-1
• ANC ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Creatinine ≤ 2 times upper limit of normal (ULN)
• ALT and AST ≤ 5 times ULN
• Total bilirubin ≤ 1.5 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No serious concurrent infection or medical illness that would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety

• No prior or other concurrent malignancy except for curatively treated carcinoma-in-situ at any site or basal cell carcinoma or squamous cell carcinoma of the skin

  • Patients who have been free of disease (any prior malignancy) for ≥ 5 years are eligible
• No porphyria
• No psoriasis, except well controlled psoriasis under the care of a specialist
• No previously documented macular degeneration or diabetic retinopathy
• No HIV positivity

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Any number and type of prior anticancer therapies allowed
• No prior mTOR inhibitors
• At least 4 weeks since prior immunotherapy (i.e., aldesleukin, interferon, CTLA-4) or chemotherapy and recovered
• At least 2 weeks since prior oral targeted therapy and recovered
• At least 4 weeks since prior and no other concurrent investigational anticancer therapy (except for vaccines)
• No other concurrent therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (i.e., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine)
• Concurrent non-enzyme inducing anticonvulsants, including felbamate, valproic acid, gabapentin, lamotrigine, tiagabine, topiramate, zonisamide, or levetiracetam allowed
• Concurrent hematologic growth factors (filgrastim [G-CSF], pegfilgrastim, epoetin alfa) allowed in patients with severe myelosuppression